Castanospermine

Identification

Name
Castanospermine
Accession Number
DB01816  (EXPT01055)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • (1S-(1α,6β,7α,8β,8αβ))-octahydro-1,6,7,8-indolizinetetrol
  • (1S,6S,7R,8R,8aR)-1,6,7,8-tetrahydroxyindolizidine
  • 1,6,7,8-tetrahydroxyoctahydroindolizine
Categories
UNII
Q0I3184XM7
CAS number
79831-76-8
Weight
Average: 189.209
Monoisotopic: 189.100107973
Chemical Formula
C8H15NO4
InChI Key
JDVVGAQPNNXQDW-TVNFTVLESA-N
InChI
InChI=1S/C8H15NO4/c10-4-1-2-9-3-5(11)7(12)8(13)6(4)9/h4-8,10-13H,1-3H2/t4-,5-,6+,7+,8+/m0/s1
IUPAC Name
(1S,6S,7R,8R,8aR)-octahydroindolizine-1,6,7,8-tetrol
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UGlucan 1,3-beta-glucosidaseNot AvailableYeast
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Castanospermine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Castanospermine is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Castanospermine is combined with 5-androstenedione.Experimental, Illicit
AbciximabCastanospermine may increase the anticoagulant activities of Abciximab.Approved
AcebutololCastanospermine may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Castanospermine is combined with Aceclofenac.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Castanospermine is combined with Acemetacin.Approved
AcenocoumarolCastanospermine may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Castanospermine.Approved, Vet Approved
AclarubicinCastanospermine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Castanospermine.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Castanospermine is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Castanospermine is combined with Alendronic acid.Approved
AliskirenCastanospermine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Castanospermine is combined with Alminoprofen.Experimental
AlprenololCastanospermine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Castanospermine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Amcinonide.Approved
AmikacinCastanospermine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideCastanospermine may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinCastanospermine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodCastanospermine may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Castanospermine is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Castanospermine is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Anisodamine.Investigational
annamycinCastanospermine may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Castanospermine.Approved
Antithrombin III humanCastanospermine may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanCastanospermine may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Castanospermine is combined with Apocynin.Investigational
ApramycinCastanospermine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Castanospermine is combined with Apremilast.Approved, Investigational
ArbekacinCastanospermine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinCastanospermine may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanCastanospermine may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Aripiprazole.Approved, Investigational
ArotinololCastanospermine may decrease the antihypertensive activities of Arotinolol.Approved
Arsenic trioxideThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Atamestane.Investigational
AtazanavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Atazanavir.Approved, Investigational
AtenololCastanospermine may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Castanospermine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Castanospermine.Approved
BalsalazideCastanospermine may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Castanospermine.Investigational
BecaplerminCastanospermine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololCastanospermine may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinCastanospermine may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Castanospermine.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Castanospermine is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Castanospermine.Approved
BenorilateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Castanospermine is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Castanospermine.Investigational
BetamethasoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BetaxololCastanospermine may decrease the antihypertensive activities of Betaxolol.Approved
BevantololCastanospermine may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Castanospermine is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Castanospermine.Approved, Investigational
BisoprololCastanospermine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinCastanospermine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololCastanospermine may decrease the antihypertensive activities of Bopindolol.Approved
BrexpiprazoleThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Brexpiprazole.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Castanospermine.Approved
BucillamineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Bucillamine.Investigational
BucindololCastanospermine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Castanospermine is combined with Bufexamac.Experimental
BufuralolCastanospermine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Bumadizone.Experimental
BumetanideCastanospermine may decrease the diuretic activities of Bumetanide.Approved
BupranololCastanospermine may decrease the antihypertensive activities of Bupranolol.Approved
BuserelinThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Buserelin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Castanospermine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Castanospermine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Castanospermine.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Castanospermine is combined with Carbaspirin calcium.Experimental
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Castanospermine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Castanospermine.Approved, Vet Approved, Withdrawn
CarteololCastanospermine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolCastanospermine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CeliprololCastanospermine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ceritinib.Approved
CertoparinCastanospermine may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Castanospermine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Castanospermine.Approved, Vet Approved
ChlorpropamideCastanospermine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Castanospermine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Castanospermine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Castanospermine.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Castanospermine.Approved
CinoxacinCastanospermine may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
Citric AcidCastanospermine may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Castanospermine.Vet Approved
CloranololCastanospermine may decrease the antihypertensive activities of Cloranolol.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Castanospermine.Approved
ClozapineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Clozapine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Castanospermine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Castanospermine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Corticosterone.Experimental
CorticotropinThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Cortisone acetate.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Castanospermine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Castanospermine is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Castanospermine.Experimental
CyclosporineCastanospermine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when Castanospermine is combined with D-Limonene.Investigational
Dabigatran etexilateCastanospermine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Dabrafenib.Approved
DalteparinCastanospermine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidCastanospermine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DanazolThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Danazol.Approved
DarexabanCastanospermine may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Darunavir.Approved
DaunorubicinCastanospermine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Castanospermine is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Castanospermine.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Castanospermine.Approved
DesirudinCastanospermine may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Castanospermine is combined with Desmopressin.Approved
DesogestrelThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Desogestrel.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Castanospermine.Approved
DextranCastanospermine may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Castanospermine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Castanospermine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Castanospermine may increase the anticoagulant activities of Dextran 75.Approved
DiazoxideThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Diazoxide.Approved
DibekacinCastanospermine may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Castanospermine.Approved, Vet Approved
DicoumarolCastanospermine may increase the anticoagulant activities of Dicoumarol.Approved
DienogestThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Dienogest.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Castanospermine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Castanospermine.Approved
DihydrostreptomycinCastanospermine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Castanospermine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Castanospermine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Castanospermine.Approved
DisopyramideCastanospermine may increase the hypoglycemic activities of Disopyramide.Approved
DoxorubicinCastanospermine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneCastanospermine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Castanospermine is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Castanospermine is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Castanospermine is combined with E-6201.Investigational
Edetic AcidCastanospermine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanCastanospermine may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Castanospermine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Castanospermine.Approved
EnoxacinCastanospermine may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinCastanospermine may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Castanospermine.Experimental
EpanololCastanospermine may decrease the antihypertensive activities of Epanolol.Experimental
EpinephrineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EpirizoleThe risk or severity of adverse effects can be increased when Castanospermine is combined with Epirizole.Approved
EpirubicinCastanospermine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneCastanospermine may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Castanospermine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Castanospermine.Approved
EquileninThe risk or severity of adverse effects can be increased when Castanospermine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Castanospermine is combined with Equilin.Approved
EsmololCastanospermine may decrease the antihypertensive activities of Esmolol.Approved
EstradiolThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
EstroneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Estrone.Approved
Estrone sulfateThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidCastanospermine may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Castanospermine.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ethinyl Estradiol.Approved
Ethyl biscoumacetateCastanospermine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ethynodiol diacetate.Approved
Etidronic acidThe risk or severity of adverse effects can be increased when Castanospermine is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Etofenamate.Approved
EtonogestrelThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Etonogestrel.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Castanospermine is combined with Evening primrose oil.Approved
EverolimusThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Everolimus.Approved
exisulindThe risk or severity of adverse effects can be increased when Castanospermine is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Castanospermine is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Castanospermine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Castanospermine.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Feprazone.Experimental
Ferulic acidCastanospermine may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Castanospermine.Approved
FingolimodCastanospermine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinCastanospermine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Castanospermine.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Castanospermine is combined with fluasterone.Investigational
FludrocortisoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Fludrocortisone.Approved
FluindioneCastanospermine may increase the anticoagulant activities of Fluindione.Investigational
FlumequineCastanospermine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Flumethasone.Approved, Vet Approved
FlunixinThe risk or severity of adverse effects can be increased when Castanospermine is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Castanospermine is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Castanospermine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Castanospermine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Castanospermine.Approved, Nutraceutical, Vet Approved
FondaparinuxCastanospermine may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumCastanospermine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Castanospermine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Fosamprenavir.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Castanospermine.Approved
FramycetinCastanospermine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideCastanospermine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Castanospermine.Investigational
GabexateCastanospermine may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinCastanospermine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinCastanospermine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Castanospermine.Approved, Withdrawn
GemifloxacinCastanospermine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinCastanospermine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinCastanospermine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ACastanospermine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Castanospermine.Investigational
GliclazideCastanospermine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideCastanospermine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideCastanospermine may increase the hypoglycemic activities of Glipizide.Approved
GlyburideCastanospermine may increase the hypoglycemic activities of Glyburide.Approved
GoserelinThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Goserelin.Approved
GPX-150Castanospermine may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinCastanospermine may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Castanospermine is combined with Guacetisal.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Castanospermine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Castanospermine is combined with HE3286.Investigational
HeparinCastanospermine may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Higenamine.Investigational
HistrelinThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Histrelin.Approved
HydralazineCastanospermine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Castanospermine.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Castanospermine.Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
Hygromycin BCastanospermine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Castanospermine.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Castanospermine is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Castanospermine is combined with Icatibant.Approved
IdarubicinCastanospermine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxCastanospermine may increase the anticoagulant activities of Idraparinux.Investigational
IloperidoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Iloperidone.Approved
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Castanospermine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Castanospermine.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Castanospermine.Approved
IndenololCastanospermine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Castanospermine is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Castanospermine.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Castanospermine is combined with Indoprofen.Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Castanospermine.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Castanospermine.Investigational
INNO-206Castanospermine may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
Insulin AspartCastanospermine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirCastanospermine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineCastanospermine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineCastanospermine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanCastanospermine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproCastanospermine may increase the hypoglycemic activities of Insulin Lispro.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Castanospermine.Approved, Investigational
IsepamicinCastanospermine may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Castanospermine is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Castanospermine is combined with Istaroxime.Investigational
KanamycinCastanospermine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Castanospermine.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Castanospermine.Approved
LabetalolCastanospermine may decrease the antihypertensive activities of Labetalol.Approved
LandiololCastanospermine may decrease the antihypertensive activities of Landiolol.Investigational
LanreotideThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Lanreotide.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Castanospermine.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Castanospermine.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Leflunomide.Approved, Investigational
LepirudinCastanospermine may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanCastanospermine may increase the anticoagulant activities of Letaxaban.Investigational
LeuprolideThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Leuprolide.Approved, Investigational
LevobunololCastanospermine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinCastanospermine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Castanospermine.Approved
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Castanospermine.Approved, Nutraceutical
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Castanospermine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Castanospermine.Approved
LonazolacThe risk or severity of adverse effects can be increased when Castanospermine is combined with Lonazolac.Experimental
LopinavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Castanospermine is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Castanospermine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Castanospermine is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Castanospermine.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Castanospermine.Vet Approved
LurasidoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Lurasidone.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Castanospermine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Castanospermine.Approved
ME-609The risk or severity of adverse effects can be increased when Castanospermine is combined with ME-609.Investigational
MecaserminCastanospermine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Castanospermine.Approved, Vet Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Castanospermine.Approved
Megestrol acetateThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MelagatranCastanospermine may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Castanospermine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Castanospermine.Approved, Vet Approved
MepindololCastanospermine may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineCastanospermine may increase the nephrotoxic activities of Mesalazine.Approved
MestranolThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Castanospermine is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Castanospermine.Approved
MethotrimeprazineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Castanospermine.Approved
MethylprednisoloneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MetipranololCastanospermine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Castanospermine.Approved
MetoprololCastanospermine may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideCastanospermine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinCastanospermine may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifepristoneCastanospermine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Castanospermine.Approved
MizoribineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Castanospermine.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Mofebutazone.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Castanospermine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Castanospermine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Castanospermine.Approved
NadololCastanospermine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinCastanospermine may increase the anticoagulant activities of Nadroparin.Approved
NafamostatCastanospermine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Castanospermine.Approved
Nalidixic AcidCastanospermine may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Castanospermine.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Castanospermine is combined with Natalizumab.Approved, Investigational
NateglinideCastanospermine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Castanospermine is combined with NCX 1022.Investigational
NeamineCastanospermine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NelfinavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Nelfinavir.Approved
NemonoxacinCastanospermine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinCastanospermine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Castanospermine is combined with Nepafenac.Approved
NetilmicinCastanospermine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NiacinThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NifenazoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Castanospermine is combined with Niflumic Acid.Approved
NilotinibThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Castanospermine is combined with Nitroaspirin.Investigational
NorethisteroneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Norethisterone.Approved
NorfloxacinCastanospermine may increase the neuroexcitatory activities of Norfloxacin.Approved
NorgestimateThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Norgestimate.Approved
OctreotideThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Octreotide.Approved, Investigational
OlanzapineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Olanzapine.Approved, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Castanospermine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Castanospermine.Approved
OlsalazineCastanospermine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Castanospermine.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Castanospermine is combined with Orgotein.Vet Approved
OtamixabanCastanospermine may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Castanospermine.Approved
Oxolinic acidCastanospermine may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololCastanospermine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Oxyphenbutazone.Withdrawn
PaliperidoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Paliperidone.Approved
PamidronateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Paramethasone.Approved
ParomomycinCastanospermine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Parthenolide.Investigational
PasireotideThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Pasireotide.Approved
PazufloxacinCastanospermine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinCastanospermine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololCastanospermine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Pentamidine.Approved
Pentosan PolysulfateCastanospermine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Castanospermine.Approved
PhenindioneCastanospermine may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonCastanospermine may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Castanospermine.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Castanospermine.Approved, Investigational
PindololCastanospermine may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidCastanospermine may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiperazineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Pipotiazine.Approved
PirarubicinCastanospermine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideCastanospermine may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pirfenidone.Investigational
Piromidic acidCastanospermine may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Castanospermine.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pirprofen.Experimental
PlazomicinCastanospermine may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinCastanospermine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Castanospermine.Approved
PractololCastanospermine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Castanospermine.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pranoprofen.Experimental
PrasteroneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Prednicarbate.Approved
PrednisoloneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Castanospermine can be increased when it is combined with Probenecid.Approved
ProgesteroneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Castanospermine is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Castanospermine is combined with Propacetamol.Approved
PropranololCastanospermine may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Castanospermine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Castanospermine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Castanospermine.Vet Approved
Protein CCastanospermine may increase the anticoagulant activities of Protein C.Approved
Protein S humanCastanospermine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeCastanospermine may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinCastanospermine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Castanospermine is combined with PTC299.Investigational
PuromycinCastanospermine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuetiapineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Castanospermine.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Castanospermine.Approved
QuinineCastanospermine may increase the hypoglycemic activities of Quinine.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Castanospermine is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Castanospermine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Castanospermine.Approved
RepaglinideCastanospermine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Castanospermine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Castanospermine is combined with Resveratrol.Experimental, Investigational
ReviparinCastanospermine may increase the anticoagulant activities of Reviparin.Approved
RibostamycinCastanospermine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Rimexolone.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Castanospermine.Investigational
RisedronateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Risedronate.Approved, Investigational
RisperidoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ritonavir.Approved, Investigational
RivaroxabanCastanospermine may increase the anticoagulant activities of Rivaroxaban.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Castanospermine.Approved
RosoxacinCastanospermine may increase the neuroexcitatory activities of Rosoxacin.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Castanospermine.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Castanospermine.Approved
RufloxacinCastanospermine may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinCastanospermine may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Castanospermine.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Castanospermine.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Castanospermine.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Castanospermine.Experimental
SaquinavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Castanospermine.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Castanospermine is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Castanospermine is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Castanospermine is combined with Serrapeptase.Investigational
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Castanospermine.Approved
SirolimusThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Sirolimus.Approved, Investigational
SisomicinCastanospermine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinCastanospermine may increase the neuroexcitatory activities of Sitafloxacin.Experimental
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Castanospermine.Approved
SotalolCastanospermine may decrease the antihypertensive activities of Sotalol.Approved
SP1049CCastanospermine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinCastanospermine may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinCastanospermine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Castanospermine.Approved
SpironolactoneCastanospermine may decrease the antihypertensive activities of Spironolactone.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Castanospermine.Investigational
SRT501The risk or severity of adverse effects can be increased when Castanospermine is combined with SRT501.Investigational
StreptomycinCastanospermine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinCastanospermine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineCastanospermine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleCastanospermine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Castanospermine.Approved
SulfisoxazoleCastanospermine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Castanospermine.Approved
SulodexideCastanospermine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Castanospermine.Investigational
SunitinibCastanospermine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Castanospermine.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Castanospermine is combined with Suxibuzone.Experimental
TacrolimusCastanospermine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Castanospermine.Approved
TalinololCastanospermine may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Castanospermine.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Castanospermine.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Castanospermine.Investigational
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Castanospermine is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Castanospermine.Approved, Investigational
TemafloxacinCastanospermine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Castanospermine.Experimental, Investigational
TemsirolimusThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Castanospermine.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Teriflunomide.Approved
TertatololCastanospermine may decrease the antihypertensive activities of Tertatolol.Experimental
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Castanospermine.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Castanospermine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tiludronic acid.Approved, Vet Approved
TimololCastanospermine may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tinoridine.Investigational
TipranavirThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tixocortol.Approved
TobramycinCastanospermine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TofacitinibCastanospermine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideCastanospermine may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideCastanospermine may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Castanospermine.Approved
TorasemideCastanospermine may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Castanospermine.Approved
TranilastThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Castanospermine.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Castanospermine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Castanospermine.Approved, Investigational
TriamcinoloneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TriamtereneCastanospermine may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Castanospermine.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Castanospermine is combined with Triptolide.Investigational
TriptorelinThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TrovafloxacinCastanospermine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
TroxerutinCastanospermine may increase the anticoagulant activities of Troxerutin.Investigational
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Castanospermine.Approved
ValrubicinCastanospermine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Castanospermine.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Castanospermine.Approved
VorinostatThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Vorinostat.Approved, Investigational
WarfarinCastanospermine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranCastanospermine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Castanospermine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Castanospermine is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Castanospermine.Approved, Investigational, Withdrawn
ZiprasidoneThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Castanospermine.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Castanospermine is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Castanospermine is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinCastanospermine may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinCastanospermine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Castanospermine.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C02256
ChemSpider
49177
BindingDB
36388
ChEBI
27860
ChEMBL
CHEMBL311226
HET
CTS
PDB Entries
1eqc / 2cbu / 2jkp / 2pwg / 2vl8 / 4iif / 5ied

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1110.0 mg/mLALOGPS
logP-2.1ALOGPS
logP-2.6ChemAxon
logS0.77ALOGPS
pKa (Strongest Acidic)12.89ChemAxon
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area84.16 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity44.44 m3·mol-1ChemAxon
Polarizability18.72 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8918
Blood Brain Barrier-0.603
Caco-2 permeable-0.5805
P-glycoprotein substrateSubstrate0.6783
P-glycoprotein inhibitor INon-inhibitor0.8961
P-glycoprotein inhibitor IINon-inhibitor0.9806
Renal organic cation transporterNon-inhibitor0.6639
CYP450 2C9 substrateNon-substrate0.8783
CYP450 2D6 substrateNon-substrate0.6942
CYP450 3A4 substrateSubstrate0.5188
CYP450 1A2 substrateNon-inhibitor0.8141
CYP450 2C9 inhibitorNon-inhibitor0.9406
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.939
CYP450 3A4 inhibitorNon-inhibitor0.9974
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9942
Ames testNon AMES toxic0.7775
CarcinogenicityNon-carcinogens0.9757
BiodegradationNot ready biodegradable0.9638
Rat acute toxicity2.3961 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6611
hERG inhibition (predictor II)Non-inhibitor0.9173
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (4 TMS)GC-MSsplash10-00o0-1932000000-28a09bc636766bb094b0
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-3900000000-75396d0a5940c9e29a57
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-006x-2900000000-079bdf1716f2d906311b
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-02ms-9800000000-e528e43709795f6c7798
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-030r-9200000000-8d9a667a9121223e0f3e
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00lr-9000000000-1798e7ef1f3d1099d86d

Taxonomy

Description
This compound belongs to the class of organic compounds known as indolizidines. These are polycyclic compounds containing an indolizidine, which is a bicyclic heterocycle containing a saturated six-member ring fused to a saturated five-member ring, one of the bridging atoms being nitrogen.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indolizidines
Sub Class
Not Available
Direct Parent
Indolizidines
Alternative Parents
Piperidines / N-alkylpyrrolidines / Trialkylamines / Secondary alcohols / 1,2-aminoalcohols / Polyols / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Indolizidine / Piperidine / N-alkylpyrrolidine / Pyrrolidine / Tertiary aliphatic amine / Tertiary amine / Secondary alcohol / 1,2-aminoalcohol / Azacycle / Polyol
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
indolizidine alkaloid (CHEBI:27860) / Indolizidine alkaloids (C02256)

Targets

Kind
Protein
Organism
Yeast
Pharmacological action
Unknown
General Function
Transferase activity
Specific Function
Major glucan 1,3-beta-glucosidase required for cell wall integrity. Beta-glucanases participate in the metabolism of beta-glucan, the main structural component of the cell wall. Can also function b...
Gene Name
XOG1
Uniprot ID
P29717
Uniprot Name
Glucan 1,3-beta-glucosidase
Molecular Weight
50037.635 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 05:03